



Information

I amino acids. VPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS VFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH HILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV NLFRLLTR DLKYVADGNL CLRTSTHPES T write Filtered White lyophilized (freeze-dried) powder. e a manual defrost freezer and avoid repeated freeze-thaw cycles 2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution philized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
cokine Zcyto21 cherichia coli. proximately 19.8 kDa, a single non-glycosylated polypeptide chain containing a mino acids. VPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS VFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH HILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV NLFRLLTR DLKYVADGNL CLRTSTHPES T write Filtered White lyophilized (freeze-dried) powder. e a manual defrost freezer and avoid repeated freeze-thaw cycles 2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution
cherichia coli. proximately 19.8 kDa, a single non-glycosylated polypeptide chain containing a mino acids. VPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS VFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH HILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV NLFRLLTR DLKYVADGNL CLRTSTHPES T write Filtered White lyophilized (freeze-dried) powder. e a manual defrost freezer and avoid repeated freeze-thaw cycles 2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution
proximately 19.8 kDa, a single non-glycosylated polypeptide chain containing a mino acids. VPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS VFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH HHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV NLFRLLTR DLKYVADGNL CLRTSTHPES T write Filtered White lyophilized (freeze-dried) powder. e a manual defrost freezer and avoid repeated freeze-thaw cycles 2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution
I amino acids. VPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS VFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH HILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV NLFRLLTR DLKYVADGNL CLRTSTHPES T write Filtered White lyophilized (freeze-dried) powder. e a manual defrost freezer and avoid repeated freeze-thaw cycles 2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution philized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
VFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH HILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV NLFRLLTR DLKYVADGNL CLRTSTHPES T write Filtered White lyophilized (freeze-dried) powder. e a manual defrost freezer and avoid repeated freeze-thaw cycles 2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution philized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
e a manual defrost freezer and avoid repeated freeze-thaw cycles 2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution philized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
2 months from date of receipt, -20 to -70 °C as supplied month, 2 to 8 °C under sterile conditions after reconstitution months, -20 to -70 °C under sterile conditions after reconstitution ophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
· · ·
recommend that this vial be briefly centrifuged prior to opening to bring the tents to the bottom. Reconstitute in sterile distilled water or aqueous buffer training 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions buld be apportioned into working aliquots and stored at \leq -20 °C. Further training should be made in appropriate buffered solutions.
ly biologically active when compared to standard. The ED as determined by anti-viral assay using human HepG2 cells infected with cephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity > 2.0 × 10 IU/mg.
I pack.
ntrifuge the vial prior to opening.
Research Use Only! Not to be used in humans.

Components and Storage

Components	5µg	100µg	500µg
Recombinant Human Interferon- lambda1/Interleukin-29	5µg	100µg	500µg

Use a manual defrost freezer and avoid repeated freeze-thaw cycles

- 12 months from date of receipt, -20 to -70 °C as supplied
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 3 months, -20 to -70 °C under sterile conditions after reconstitution

Quality Control	(Opening)	
Purity	> 97 % by SDS-PAGE and HPLC analyses.	Plane bare no un
Endotoxin	Less than 1 EU/ $_{\mu}$ g of rHuIFN- $_{\lambda}$ 1/IL-29 as det	ermined by LAL method.

Description

IL-28A, IL-28B, and IL-29, also named interferon- λ 2 (IFN- λ 2), IFN- λ 3, and IFN- λ 1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 R β) and a novel IL-28 receptor α (IL-28 R α , also known as IFN- λ R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.

Reference

1. Miller EK, Hernandez JZ, Wimmenauer V, et al. 2012. Am J Respir Crit Care Med, 185: 508-16

- 2. Li Y, Xie J, Xu X, et al. 2012. Protein Cell,
- 3. Jordan WJ, Eskdale J, Srinivas S, et al. 2007. Genes Immun, 8: 254-61
- 4. Pekarek V, Srinivas S, Eskdale J, et al. 2007. Genes Immun, 8: 177-80
- 5. Megjugorac NJ, Gallagher GE, Gallagher G. 2010. Blood, 115: 4185-90.

